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Aminoglutethimide (AG) inhibits steroid bio-
synthesis and the peripheral conversion of
androgens to oestrogens (Santen et al., 1978;
Dexter et al., 1967). Aminoglutethimide has proved
to be an effective therapy in advanced breast cancer
with response rates of 37.5-50% (Wells et al., 1978;
Harris et al., 1983) and duration of response similar
to adrenalectomy. However, blood dyscrasias have
been reported in -1% of patients. We have seen
two patients who developed severe agranulocytosis
while taking aminoglutethimide and we describe
possible mechanisms and predisposing factors.
A 62-year old woman presented with local recurrence of
breast cancer and bone pain 2 years after primary treat-
ment.
She started treatment with aminoglutethimide 250mg
three times a day and hydrocortisone 20mg twice a day
and 10 days afterwards she developed a skin rash. The
rash faded after 5 days. A full blood count on the 28th
day after starting showed agranulocytosis and no
granulocytes were visible on a peripheral blood film. She
developed a sore mouth and mouth ulcers which
improved after 2 weeks. She continued aminoglutethimide
and hydrocortisone and 3 weeks after the episode of
agranulocytosis her peripheral blood film was normal.
Marrow aspirated at the same time showed normal
haemopoiesis and marrow infiltration with malignant
cells. An abnormal alkaline phosphatase and yGT became
transiently worse during the episode of agranulocytosis.
She continued on aminoglutethimide and hydro-
cortisone and had a complete regression of skin nodules
and sclerosis of her lytic bone secondaries. Her remission
lasted for 18 months.
A 50-year old woman was treated by radical
mastectomy and adjuvant radiotherapy to the right chest
wall and right supraclavicular fossa. She was started on
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adjuvant endocrine therapy with aminoglutethimide
250mg three times a day and hydrocortisone 20mg twice
a day. Seven weeks later she had a fever, sore throat, felt
generally unwell and had mild nausea. She was treated
with cephalexin by her general practitioner with no
improvement. A week later she had a low white cell
count, total 0.8 x 1091-1; 34% granulocytes. She was seen
in clinic after a further week and aminoglutethimide was
stopped. The white cell count had started to improve
while on aminoglutethimide (total count, 1.1 x 1091-1;
40% granulocytes). Marrow aspirate showed a hypo-
cellular marrow with normal erythroid cells and normal
megakaryocytes. There were some large early granulocytic
cells present. Repeat marrow aspiration 3 weeks after
recovery showed a cellular marrow with normal develop-
ment of all cell lines.
Marrow was assayed for granulocyte/macrophage
precursors (CFUc) in a semi solid colony assay
(Barrett et al., 1976). Normal marrow and marrow
from patient 2 was preincubated with plasma from
patient 2 taken before starting aminoglutethimide,
during and after the episode of agranulocytosis.
The effects of a final concentration of 10% and
50% patient's plasma were studied on normal
marrow and 50% patient's plasma on autologous
marrow. The preincubation was for 1.5h at 370C
and cells were washed and then plated. Colonies
and clusters were read after 10 days incubation. All
assays were performed in triplicate.
Colony formation in marrow aspirated from
patient 2 after recovery from agranulocytosis was
very poor. Plasma containing aminoglutethimide
suppressed colony formation further (Table I).
There was a suppressive effect also on normal
marrow, with 50% patient's plasma, while on
aminoglutethimide.
Plasma levels were measured by reverse phase
high pressure liquid chromatography after dichloro-
methane extraction, using 2 internal standards.
The levels for patient 1 were 0.4Mgml-1 amino-
glutethimide and 4.2 ugml - I N acetyl amino-
glutethimide and for patient 2, 3.2jugml-1
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Table I Effects of patient plasma on normal and patient's own marrow
Normal bone marrow Patient bone marrow




50% 18+2 56+2 0 2.6+0.6
Pretreatment plasma
10% 10+0 45+6
50% 17.7+6 50+11 2.6+0.6 25+5
Plasma during treatment
10% 13.5+5 39+2
50% 13+5 38+2 0 13+6
Convalescent plasma
10% 14+3 45.5+8
50% 17.3+3 69+9 0.6+0.6 20+10
Bone marrow cells were incubated for A2 hours with patient's plasma at a final
concentration of 10% or 50% before being plated on agar feeder layers. Colony growth
was counted on day 10.
aminoglutethimide and 4.0 igml-1 N acetyl amino-
glutethimide. These concentrations are in the range
found in 49 other patients taking aminoglute-
thimide (aminoglutethimide mean 4.8+ 5.1 s.d.,
range 0.4-24.4 gml- 1; N acetyl aminoglutethimide
mean 1.9+1.3s.d., range 0.3-5.4 igml-1). The
ratio of N acetyl aminoglutethimide to aminoglute-
thimide was higher in patient 2 than in any other
patient (10.5) (patient 1, 1.25; other patients mean
0.83+ 1.59s.d., range 0.5-8.77).
Oestrone, oestradiol, testosterone and dehydro-
epiandrosterone sulphate (DHAS) were measured
by radioimmunoassay using reagents in the WHO
matched reagents scheme. The methods and assays
have been described in detail (Harris et al., 1982;
Harris et al., 1983).
Plasma hormones were similar to those observed
in 45 postmenopausal patients and 17 pre-
menopausal patients taking aminoglutethimide and
hydrocortisone (data not shown).
Both patients had severe agranulocytosis, which
recovered rapidly, and had normal platelet counts
and haemoglobin. The only drugs they were
receiving were aminoglutethimide and hydro-
cortisone.
An immune mechanism is unlikely because of the
mild effects of the patient's plasma containing
aminoglutethimide on normal marrow. Others have
shown much more marked inhibition of CFUc
formation in normal and autologous marrow in
amidopyrine (Barnett et al., 1976), quinidine
(Keltan et al., 1979) and phenytoin (Taetle et al.,
1979) induced agranulocytosis, and in those cases
the patient's serum was necessary for the effect. In
other cases with quinine, amiodaquine and
phenytoin, there was an increased sensitivity of the
marrow to normal therapeutic plasma levels
(Young & Vincent, 1980; Lind et al., 1973;
Sutherland et al., 1977; Smith et al., 1977).
One detailed case of pancytopenia due to amino-
glutethimide has been reported (Lawrence et al.,
1978), 4 cases of agranulocytosis (Austerlitz, 1982;
Kampel & Kurman, 1984; Young et al., 1984; Gez
& Sulkes, 1984) and 2 of thrombocytopenia (Ragaz
et al., 1984; Ardman & Rudders, 1982). In the
majority of cases, there have been predisposing
factors present likely to compromise marrow
reserve. These include recent prior extensive radio-
therapy (Austerlitz, 1982; Young et al., 1984; Ragaz
et al., 1984; Ardman & Rudders, 1982), combina-
tion chemotherapy (Young et al., 1984; Gez &
Sulkes, 1984; Ragaz et al., 1984; Ardman &
Rudders, 1982), marrow infiltration with carcinoma
(Austerlitz, 1982; Ragaz et al., 1984; Ardman &
Rudders, 1982) or recent adjuvant chemotherapy
(Lawrence et al., 1978). In two cases of thrombo-
cytopenia, rechallenge with aminoglutethimide
produced thrombocytopenia again (Ragaz et al.,
1984; Ardman & Rudders, 1982). Our 2 cases also
had predisposing factors likely to deplete bone
marrow stem cell reserve, or had intrinsically poor
CFUc forming capacity (case 2). Some patients
who have recovered from drug induced agranulo-
cytosis have poor CFUc growth, and it is suggested
that this predisposed them to drug induced
agranulocytosis (Parmentier et al., 1978).
The most likely reason for the agranulocytosis
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marrow with poor stem cell reserve. In a normal
marrow, the effect could easily be compensated
(Table I).
Pharmacokinetic differences were not evident in
our patients, since plasma levels of aminoglute-
thimide and its acetylated metabolite were similar
to levels in other patients, although the ratio of
acetylated to parent compound was high in patient
2.
An unusual feature of both patients is that the
granulocyte count had started to rise again while
on the drug. This again suggests a direct effect that
could be compensated by an increase in stem cell
numbers. Gez and Sulkes (1984) reinstituted amino-
glutethimide after agranulocytosis recovered and
there was no repeated suppression of granulocyte
count.
Another possible site of the adverse effect of
aminoglutethimide may be the marrow fat cell. The
growth of mammalian marrow in long-term
continuous culture requires the presence of fat cells
(Dexter et al., 1977). One of the effects of amino-
glutethimide is to inhibit the aromatase enzymes
that convert androgens to oestrogens in peripheral
fat (Santen et al., 1978). Aromatisation activity is
present in normal human marrow fat cells and is
inhibited by aminoglutethimide in vitro (Frisch et
al., 1980).
The incidence of blood dyscrasia due to amino-
glutethimide is 1%, since we have treated 228
patients with aminoglutethimide and only observed
agranulocytosis in 2 patients. Lawrence et al. (1978)
described one case of pancytopenia and they have
treated 153 patients. Ragaz et al. (1984) found one
severe case of thrombocytopenia and 2 mild cases
(platelets >60 x 1091 1) in 141 patients (2%).
However, compared to chemotherapy this risk is
small and recovery is very rapid. The onset of
agranulocytosis has been within 10 weeks of
starting therapy, and it seems unlikely that routine
blood counts would detect a trend in falling white
count. Patients should be advised to report to their
doctors if they develop sore throats, mouth ulcers
or influenza-like symptoms.
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